
doi: 10.1002/ajh.25607
pmid: 31396979
AbstractNodular lymphocyte predominant Hodgkin lymphoma (NLPHL) can present with different histopathological growth patterns. The impact of these histopathological growth patterns on relapse characteristics is unknown. We therefore analyzed paired biopsies obtained at initial diagnosis and relapse from 33 NLPHL patients who had received first‐line treatment within German Hodgkin Study Group (GHSG) trial protocols, and from a second cohort of 41 relapsed NLPHL patients who had been treated outside GHSG studies. Among the 33 GHSG patients, 21 patients presented with a typical growth pattern at initial diagnosis, whereas 12 patients had a variant histology. The histopathological growth patterns at initial diagnosis and at relapse were consistent in 67% of cases. A variant histology at initial diagnosis was associated with a shorter median time to lymphoma recurrence (2.8 vs 5.2 years; P = .0219). A similar tendency towards a shorter median time to lymphoma recurrence was observed for patients presenting with a variant histology at relapse, irrespective of the growth pattern at initial diagnosis. Results obtained from the 41 NLPHL patients who had been treated outside GHSG studies were comparable (median time to lymphoma recurrence for variant histology vs typical growth pattern at initial diagnosis: 1.5 vs 7.0 years). In conclusion, the histopathological growth pattern remains consistent at relapse in the majority of NLPHL cases, and has major impact on the time of relapse.
Adult, Male, ddc:610, Hodgkin disease, Biopsy, Hematopoietic Stem Cell Transplantation, 610, Lymphogranulomatose, Combined Modality Therapy, Hodgkin Disease, Transplantation, Autologous, Disease-Free Survival, Recurrence, Germany, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Rituximab, info:eu-repo/classification/ddc/610, Follow-Up Studies
Adult, Male, ddc:610, Hodgkin disease, Biopsy, Hematopoietic Stem Cell Transplantation, 610, Lymphogranulomatose, Combined Modality Therapy, Hodgkin Disease, Transplantation, Autologous, Disease-Free Survival, Recurrence, Germany, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Rituximab, info:eu-repo/classification/ddc/610, Follow-Up Studies
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 28 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
